{"id":591,"date":"2020-03-16T09:30:49","date_gmt":"2020-03-16T09:30:49","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=591"},"modified":"2020-03-16T09:30:49","modified_gmt":"2020-03-16T09:30:49","slug":"nota-informativa-muh-fv-4-2020","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2020\/03\/16\/nota-informativa-muh-fv-4-2020\/","title":{"rendered":"Nota Informativa MUH (FV), 4\/2020"},"content":{"rendered":"<table class=\"portada\" border=\"0\">\n<tbody>\n<tr>\n<td><a href=\"https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2020-seguridad-1\/esmya-acetato-de-ulipristal-suspension-de-comercializacion-como-medida-cautelar-mientras-se-revalua-su-relacion-beneficio-riesgo\/\">Esmya (acetato de ulipristal): suspensi\u00f3n de comercializaci\u00f3n como medida cautelar mientras se reval\u00faa su relaci\u00f3n beneficio-riesgo<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Esmya (acetato de ulipristal): suspensi\u00f3n de comercializaci\u00f3n como medida cautelar mientras se reval\u00faa su relaci\u00f3n beneficio-riesgo<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-591","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=591"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/591\/revisions"}],"predecessor-version":[{"id":592,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/591\/revisions\/592"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}